Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The cleavage site of C5 from man and animals as a common target for neutralizing human monoclonal antibodies: in vitro and in vivo studies

1 Oct 2002

Abstract excerpt

The isolation of an anti-C5 single-chain fragment variable (scFv) antibody, TS-A12/22, from a human phage display library, is described. This antibody inhibits the activation of C5 and the assembly of the terminal complement complex implicated in cell and tissue damage. Using antibody-sensitized sheep erythrocytes and rabbit red cells as target cells in hemolytic assays, we found that TS-A12/22 inhibited the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glycosylation and Glycoproteins Research
Share to Monoclonal and Polyclonal Antibodies Research
Share to Protein purification and stability

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 12355429
DOI: 10.1002/1521-4141(2002010)32:10<2773::aid-immu2773>3.0.co;2-g

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The cleavage site of C5 from man and animals as a common target for neutralizing human monoclonal antibodies: in vitro and in vivo studiesPMID 12355429Read ↗

C3d-Targeted factor H inhibits tissue complement in disease models and reduces glomerular injury without affecting circulating complementSemantic proximity Read ↗

Inhibition of cleavage of human complement component C5 and the R885H C5 variant by two distinct high affinity anti-C5 nanobodiesSemantic proximity Read ↗

Inhibition of cleavage of human complement component C5 and the R885H C5 variant by two distinct high affinity anti-C5 nanobodiesSemantic proximity Read ↗

A Highly Functional Synthetic Phage Display Library Containing over 40 Billion Human Antibody ClonesSemantic proximity Read ↗

High Affinity Humanized Antibodies without Making Hybridomas; Immunization Paired with Mammalian Cell Display and In Vitro Somatic HypermutationSemantic proximity Read ↗

Eculizumab treatment efficiently prevents C5 cleavage without C5a generation in vivoSemantic proximity Read ↗

Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5.Semantic proximity Read ↗

Cloning and expression of a novel human antibody–antigen pair associated with Felty's syndromeSemantic proximity Read ↗

Specific binding of the pathogenic prion isoform: development and characterization of a humanized single-chain variable antibody fragment.Semantic proximity Read ↗

Fine mapping of inhibitory anti-alpha5 monoclonal antibody epitopes that differentially affect integrin-ligand binding.Semantic proximity Read ↗

Identification and Characterization of a Peptide That Specifically Binds the Human, Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody b12Semantic proximity Read ↗

Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.